Live
- Nizamabad MP Dharmapuri Arvind and Jagtial MLA Dr. Sanjay Kumar Meet CM Revanth Reddy
- Hyderabad CP CV Anand Issues Stern Warning to Bouncers
- MP Laxman Criticizes Police Conduct, Calls for Support for Victims' Families
- Fire Breaks Out in Kachiguda-Chennai Egmore Express, Passengers Evacuated Safely
- CM Revanth Reddy Condemns Attacks on Film Personalities' Homes, Calls for Strict Action
- Victory Venkatesh and Nandamuri Balakrishna to Set Screens on Fire with Unstoppable Season 4
- Over 71.81 crore Ayushman Bharat Health Account numbers generated: Centre
- In special gesture, Kuwait's Prime Minister sees-off PM Modi at airport after conclusion of historic visit
- Veer crowned PGTI Ranking champion, Shaurya wins emerging player honour
- Sr National Badminton: Unseeded Rounak Chauhan, Adarshini Shri reach singles semis
Biocon shares decline nearly 4 pc after Q1 earnings
Biocon Executive Chairperson Kiran Mazumdar-Shaw
Shares of biotechnology major Biocon on Friday dropped nearly 4 per cent after the company reported a 26.30 per cent decline in its consolidated net profit for the quarter ended June 30, 2020.
New Delhi: Shares of biotechnology major Biocon on Friday dropped nearly 4 per cent after the company reported a 26.30 per cent decline in its consolidated net profit for the quarter ended June 30, 2020.
The stock fell 3.52 per cent to close at Rs 415.15 on the BSE. During the day, it dipped 3.84 per cent to Rs 413.75. On the NSE, it was down 3.69 per cent to close at Rs 414.40. Biocon has reported a 26.30 per cent decline in its consolidated net profit at Rs 167.8 crore for the quarter ended June 30, 2020.
The company had posted a net profit of Rs 227.7 crore for the corresponding period of the previous fiscal, Biocon said in a late night filing to the BSE. Consolidated revenue from operations of the company stood at Rs 1,671.3 crore for the quarter under consideration as against Rs 1,458.9 crore for the same period a year ago, it added.
"Profitability for the quarter was impacted due to higher research and development spend, lower profit share in the biosimilars business, and lower profitability in the research services segment," Biocon Executive Chairperson Kiran Mazumdar-Shaw said.
